Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]

Abstract

Ranzenigo M, Gianotti N, Galli L, et al. Drug Des Devel Ther. 2022;16:1975–1982. Page 1975, Abstract, Results, line five, the text “the ongoing regimen was based on NNRTIs in 37 (35%) and on InSTIs in 69 (65%)” should read “the ongoing regimen was based on NNRTIs in 32 (30.2%) and on InSTIs in 74 (69.8%)”. Page 1977, Results, last paragraph, line one, the text “a longer exposure” should read “a shorter exposure”. Page 1980, first paragraph, lines one and two, the text “(a longer history of infection and a previous diagnosis of AIDS)” should read “(a previous diagnosis of AIDS)”. Page 1980, Table 2, last row, the category INSTI-based vs NNRTI-based for the BL ART (type of non-PI regimen) characteristic is incorrect and should read “NNRTI-based vs INSTI-based”. The correct Table 2is shown below. Table 2 Factors Associated with the Switch to D/C/F/TAF The authors apologise for the errors and advise they do not affect the results of the paper.

Keywords

• treatment switching
• anti-retroviral agents
• hiv protease inhibitors
• adverse drug events
• sustained virologic response